• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

双特异性工程抗体结构域(纳米抗体)与 HIV-1 中和表位和 FcRn 非竞争性相互作用。

Bispecific engineered antibody domains (nanoantibodies) that interact noncompetitively with an HIV-1 neutralizing epitope and FcRn.

机构信息

Protein Interactions Group, Frederick National Laboratory for Cancer Research, National Institutes of Health, Frederick, Maryland, United States of America.

出版信息

PLoS One. 2012;7(8):e42288. doi: 10.1371/journal.pone.0042288. Epub 2012 Aug 7.

DOI:10.1371/journal.pone.0042288
PMID:22879932
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC3413693/
Abstract

Libraries based on an isolated human immunoglobulin G1 (IgG1) constant domain 2 (CH2) have been previously diversified by random mutagenesis. However, native isolated CH2 is not very stable and the generation of many mutations could lead to an increase in immunogenicity. Recently, we demonstrated that engineering an additional disulfide bond and removing seven N-terminal residues results in an engineered antibody domain (eAd) (m01s) with highly increased stability and enhanced binding to human neonatal Fc receptor (FcRn) (Gong et al, JBC, 2009 and 2011). We and others have also previously shown that grafting of the heavy chain complementarity region 3 (CDR-H3 (H3)) onto cognate positions of the variable domain leads to highly diversified libraries from which a number of binders to various antigens have been selected. However, grafting of H3s to non-cognate positions in constant domains results in additional residues at the junctions of H3s and the CH2 framework. Here we describe a new method based on multi-step PCR that allows the precise replacement of loop FG (no changes in its flanking sequences) by human H3s from another library. Using this method and limited mutagenesis of loops BC and DE we generated an eAd phage-displayed library. Panning of this library against an HIV-1 gp41 MPER peptide resulted in selection of a binder, m2a1, which neutralized HIV-1 isolates from different clades with modest activity and retained the m01s capability of binding to FcRn. This result provides a proof of concept that CH2-based antigen binders that also mimic to certain extent other functions of full-size antibodies (binding to FcRn) can be generated; we have previously hypothesized that such binders can be made and coined the term nanoantibodies (nAbs). Further studies in animal models and in humans will show how useful nAbs could be as therapeutics and diagnostics.

摘要

基于人免疫球蛋白 G1(IgG1)恒定域 2(CH2)的文库已经通过随机诱变进行了多样化。然而,天然分离的 CH2 不太稳定,并且产生许多突变可能会导致免疫原性增加。最近,我们证明,通过工程化额外的二硫键并去除七个 N 端残基,可以产生具有高度增加稳定性和增强与人新生儿 Fc 受体(FcRn)结合的工程抗体域(eAd)(m01s)(Gong 等人,JBC,2009 年和 2011 年)。我们和其他人以前还表明,将重链互补决定区 3(CDR-H3(H3))嫁接在可变域的同源位置会导致高度多样化的文库,从中选择了许多针对各种抗原的结合物。然而,将 H3 嫁接在恒定域的非同源位置会导致 H3 与 CH2 框架的连接处有额外的残基。在这里,我们描述了一种基于多步 PCR 的新方法,该方法允许精确地用来自另一个文库的人 H3 替换 FG 环(其侧翼序列不变)。使用这种方法和对 BC 和 DE 环的有限诱变,我们生成了一个 eAd 噬菌体展示文库。该文库针对 HIV-1 gp41 MPER 肽进行淘选,选择了一种结合物 m2a1,该结合物能够中和来自不同分支的 HIV-1 分离株,具有适度的活性,并保留了 m01s 与 FcRn 结合的能力。这一结果提供了一个概念验证,即也在某种程度上模拟全长抗体其他功能(与 FcRn 结合)的基于 CH2 的抗原结合物可以被生成;我们以前假设可以制造这种结合物,并将其命名为纳米抗体(nAbs)。在动物模型和人类中的进一步研究将表明 nAbs 作为治疗剂和诊断剂的有用性。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a05b/3413693/aa122357eec5/pone.0042288.g010.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a05b/3413693/c275f3abe7e9/pone.0042288.g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a05b/3413693/f3133e508930/pone.0042288.g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a05b/3413693/3c41ee9bfba8/pone.0042288.g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a05b/3413693/476d866d13d5/pone.0042288.g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a05b/3413693/b84d999546b8/pone.0042288.g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a05b/3413693/77e800d8ace8/pone.0042288.g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a05b/3413693/3d974360c6f6/pone.0042288.g007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a05b/3413693/2b63e3b392c4/pone.0042288.g008.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a05b/3413693/9a5995532422/pone.0042288.g009.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a05b/3413693/aa122357eec5/pone.0042288.g010.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a05b/3413693/c275f3abe7e9/pone.0042288.g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a05b/3413693/f3133e508930/pone.0042288.g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a05b/3413693/3c41ee9bfba8/pone.0042288.g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a05b/3413693/476d866d13d5/pone.0042288.g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a05b/3413693/b84d999546b8/pone.0042288.g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a05b/3413693/77e800d8ace8/pone.0042288.g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a05b/3413693/3d974360c6f6/pone.0042288.g007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a05b/3413693/2b63e3b392c4/pone.0042288.g008.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a05b/3413693/9a5995532422/pone.0042288.g009.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a05b/3413693/aa122357eec5/pone.0042288.g010.jpg

相似文献

1
Bispecific engineered antibody domains (nanoantibodies) that interact noncompetitively with an HIV-1 neutralizing epitope and FcRn.双特异性工程抗体结构域(纳米抗体)与 HIV-1 中和表位和 FcRn 非竞争性相互作用。
PLoS One. 2012;7(8):e42288. doi: 10.1371/journal.pone.0042288. Epub 2012 Aug 7.
2
A large human domain antibody library combining heavy and light chain CDR3 diversity.一个结合了重链和轻链 CDR3 多样性的大型人类结构域抗体文库。
Mol Immunol. 2010 Jan;47(4):912-21. doi: 10.1016/j.molimm.2009.09.039. Epub 2009 Nov 1.
3
Shortened engineered human antibody CH2 domains: increased stability and binding to the human neonatal Fc receptor.缩短的工程化人抗体 CH2 结构域:提高稳定性和与人新生儿 Fc 受体的结合能力。
J Biol Chem. 2011 Aug 5;286(31):27288-93. doi: 10.1074/jbc.M111.254219. Epub 2011 Jun 13.
4
Characterization and screening of IgG binding to the neonatal Fc receptor.IgG与新生儿Fc受体结合的特性鉴定与筛选
MAbs. 2014 Jul-Aug;6(4):928-42. doi: 10.4161/mabs.28744. Epub 2014 Apr 7.
5
HIV-1 gp140 epitope recognition is influenced by immunoglobulin DH gene segment sequence.HIV-1 gp140表位识别受免疫球蛋白DH基因片段序列影响。
Immunogenetics. 2016 Feb;68(2):145-55. doi: 10.1007/s00251-015-0890-x. Epub 2015 Dec 19.
6
Characterization of a high-affinity human antibody with a disulfide bridge in the third complementarity-determining region of the heavy chain.鉴定重链第三个互补决定区带有二硫键的高亲和力人源抗体。
J Mol Recognit. 2012 Mar;25(3):125-35. doi: 10.1002/jmr.1168.
7
Engineered soluble monomeric IgG1 CH3 domain: generation, mechanisms of function, and implications for design of biological therapeutics.工程化可溶性单体 IgG1 CH3 结构域:功能的产生机制及其对生物治疗药物设计的意义。
J Biol Chem. 2013 Aug 30;288(35):25154-25164. doi: 10.1074/jbc.M113.484154. Epub 2013 Jul 18.
8
Computational design of protein antigens that interact with the CDR H3 loop of HIV broadly neutralizing antibody 2F5.与HIV广谱中和抗体2F5的互补决定区H3环相互作用的蛋白质抗原的计算设计。
Proteins. 2014 Oct;82(10):2770-82. doi: 10.1002/prot.24641. Epub 2014 Jul 31.
9
Ablation of the complementarity-determining region H3 apex of the anti-HIV-1 broadly neutralizing antibody 2F5 abrogates neutralizing capacity without affecting core epitope binding.抗 HIV-1 广泛中和抗体 2F5 的互补决定区 H3 顶端的消融消除了中和能力而不影响核心表位结合。
J Virol. 2010 May;84(9):4136-47. doi: 10.1128/JVI.02357-09. Epub 2010 Feb 10.
10
Construction of a large phage-displayed human antibody domain library with a scaffold based on a newly identified highly soluble, stable heavy chain variable domain.基于新鉴定出的高溶解性、稳定的重链可变域构建具有支架的大型噬菌体展示人抗体结构域文库。
J Mol Biol. 2008 Oct 10;382(3):779-89. doi: 10.1016/j.jmb.2008.07.054. Epub 2008 Jul 26.

引用本文的文献

1
Recent Advances in the Molecular Design and Applications of Multispecific Biotherapeutics.多特异性生物治疗药物的分子设计与应用的最新进展
Antibodies (Basel). 2021 Mar 30;10(2):13. doi: 10.3390/antib10020013.
2
An engineered human IgG1 CH2 domain with decreased aggregation and nonspecific binding.具有降低聚集性和非特异性结合的工程化人 IgG1 CH2 结构域。
MAbs. 2020 Jan-Dec;12(1):1689027. doi: 10.1080/19420862.2019.1689027.
3
Engineering of Fc Fragments with Optimized Physicochemical Properties Implying Improvement of Clinical Potentials for Fc-Based Therapeutics.

本文引用的文献

1
Pharmacokinetics of engineered human monomeric and dimeric CH2 domains.工程化人单体和二聚体 CH2 结构域的药代动力学。
MAbs. 2012 Jul-Aug;4(4):466-74. doi: 10.4161/mabs.20652. Epub 2012 Jul 1.
2
Candidate antibody-based therapeutics against HIV-1.针对 HIV-1 的候选抗体类治疗药物。
BioDrugs. 2012 Jun 1;26(3):143-62. doi: 10.2165/11631400-000000000-00000.
3
Cross-reactive HIV-1-neutralizing human monoclonal antibodies identified from a patient with 2F5-like antibodies.从一位具有 2F5 样抗体的患者中鉴定出的交叉反应性 HIV-1 中和人源单克隆抗体。
具有优化物理化学性质的Fc片段工程,意味着基于Fc的治疗药物临床潜力的提升。
Front Immunol. 2018 Jan 8;8:1860. doi: 10.3389/fimmu.2017.01860. eCollection 2017.
4
Single-Domain Antibodies As Therapeutics against Human Viral Diseases.作为抗人类病毒性疾病疗法的单域抗体
Front Immunol. 2017 Dec 13;8:1802. doi: 10.3389/fimmu.2017.01802. eCollection 2017.
5
Systemic and topical use of monoclonal antibodies to prevent the sexual transmission of HIV.全身和局部使用单克隆抗体以预防艾滋病毒的性传播。
AIDS. 2017 Jul 17;31(11):1505-1517. doi: 10.1097/QAD.0000000000001521.
6
Engineered antibody CH2 domains binding to nucleolin: Isolation, characterization and improvement of aggregation.与核仁素结合的工程化抗体CH2结构域:聚集的分离、表征及改善
Biochem Biophys Res Commun. 2017 Apr 1;485(2):446-453. doi: 10.1016/j.bbrc.2017.02.058. Epub 2017 Feb 13.
7
Fc Engineering for Developing Therapeutic Bispecific Antibodies and Novel Scaffolds.用于开发治疗性双特异性抗体和新型支架的Fc工程
Front Immunol. 2017 Jan 26;8:38. doi: 10.3389/fimmu.2017.00038. eCollection 2017.
8
Engineered IgG1-Fc--one fragment to bind them all.工程化IgG1-Fc——一种能结合所有物质的片段。
Immunol Rev. 2016 Mar;270(1):113-31. doi: 10.1111/imr.12385.
9
High Affinity Binders to EphA2 Isolated from Abdurin Scaffold Libraries; Characterization, Binding and Tumor Targeting.从阿卜杜林支架文库中分离得到的EphA2高亲和力结合物;表征、结合及肿瘤靶向性
PLoS One. 2015 Aug 27;10(8):e0135278. doi: 10.1371/journal.pone.0135278. eCollection 2015.
10
Engineered antibody domains with significantly increased transcytosis and half-life in macaques mediated by FcRn.经FcRn介导在猕猴体内具有显著增强的转胞吞作用和半衰期的工程化抗体结构域。
MAbs. 2015;7(5):922-30. doi: 10.1080/19420862.2015.1067353.
J Virol. 2011 Nov;85(21):11401-8. doi: 10.1128/JVI.05312-11. Epub 2011 Aug 31.
4
Shortened engineered human antibody CH2 domains: increased stability and binding to the human neonatal Fc receptor.缩短的工程化人抗体 CH2 结构域:提高稳定性和与人新生儿 Fc 受体的结合能力。
J Biol Chem. 2011 Aug 5;286(31):27288-93. doi: 10.1074/jbc.M111.254219. Epub 2011 Jun 13.
5
Design, expression and characterization of a soluble single-chain functional human neonatal Fc receptor.可溶性单链功能性人新生儿Fc受体的设计、表达与表征
Protein Expr Purif. 2011 Sep;79(1):66-71. doi: 10.1016/j.pep.2011.03.012. Epub 2011 Mar 29.
6
Crystal structure of a non-neutralizing antibody to the HIV-1 gp41 membrane-proximal external region.HIV-1 gp41 膜近端外部区域非中和抗体的晶体结构。
Nat Struct Mol Biol. 2010 Dec;17(12):1492-4. doi: 10.1038/nsmb.1944. Epub 2010 Nov 14.
7
Design of next-generation protein therapeutics.下一代蛋白质治疗药物的设计。
Curr Opin Chem Biol. 2010 Aug;14(4):520-8. doi: 10.1016/j.cbpa.2010.06.175. Epub 2010 Jul 16.
8
X-ray crystal structures of monomeric and dimeric peptide inhibitors in complex with the human neonatal Fc receptor, FcRn.单体和二聚体肽抑制剂与人新生儿 Fc 受体 FcRn 复合物的 X 射线晶体结构。
J Biol Chem. 2010 Sep 3;285(36):27694-701. doi: 10.1074/jbc.M110.120667. Epub 2010 Jun 30.
9
Therapeutic antibodies, vaccines and antibodyomes.治疗性抗体、疫苗和抗体组学。
MAbs. 2010 May-Jun;2(3):347-56. doi: 10.4161/mabs.2.3.11779. Epub 2010 May 14.
10
Engineered CH2 domains (nanoantibodies).工程化 CH2 结构域(纳米抗体)。
MAbs. 2009 Jan-Feb;1(1):26-8. doi: 10.4161/mabs.1.1.7480.